What to do if you are resistant to Ramucirumab

If patients develop resistance to Ramucirumab, they should communicate with their doctors in a timely manner. Depending on the specific tumor type and resistance mechanism, doctors may recommend other targeted therapy drugs. These drugs may target different signaling pathways or molecular targets in order to achieve better therapeutic effects. Combining chemotherapy or radiotherapy may be an effective option to deal with drug resistance. This can put pressure on tumor cells through different mechanisms and reduce the development of drug resistance.

The pharmacokinetics (PK) of ramucizumab, a human monoclonal antibody (IgG1) directed against vascular endothelial growth factor receptor 2 (VEGFR2), was studied in patients with various cancers at doses ranging from 6 to 12 mg/kg administered every two or three weeks. Based on population pharmacokinetic analysis, the pharmacokinetic profiles of ramucirumab are similar in patients with different cancer types. At doses of 8 mg/kg and above, systemic exposure to ramucirumab increased proportionally with the dose, reaching steady-state concentrations at approximately 12 weeks.

Ramosizumab is usually an injection preparation. The original drug has been on the market in China, but it has been on the market for a short time and has not been included in the medical insurance. The price of 100mg/10mL per box may be around RMB 5,000, and the price of 500mg/50mL per box may be around RMB 17,000. The price of the original Hong Kong version of 100mg/10mL may be around RMB 8,400 per box, and the price of 500mg/50mL per box may be around RMB 28,000 (the price may fluctuate due to exchange rates), and their pharmaceutical ingredients are basically the same. Currently, there are no generic drugs produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.